• In late June 2026, Microbot Medical announced a Letter of Agreement with Sanmina to manufacture LIBERTY, an FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, adding a second, diversified production site aimed at improving efficiency and lowering costs as global demand builds.
• Over the same period, Sanmina’s role as a key manufacturing partner was underscored by its simultaneous reshuffle across several Russell indexes, potentially broadening its visibility with institutional investors while it supports LIBERTY’s planned scale-up across the U.S., Israel and prospective CE Mark markets.
• Next, we’ll examine how Sanmina’s new LIBERTY manufacturing role with Microbot Medical could reshape its investment narrative around growth and efficiency.

Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Sanmina Investment Narrative Recap

To own Sanmina, you need to believe it can turn its scale in complex manufacturing into durable earnings growth while managing big swings in customer and product mix. In the near term, the key catalyst is execution on the ZT Systems acquisition and associated AI data center programs, while the biggest risk remains inventory and working capital tied to that deal. The new LIBERTY manufacturing role and index reshuffle support the story but do not materially change those near term drivers.

The most relevant recent development alongside the Microbot agreement is Sanmina’s broad move into the Russell 1000 and Midcap indexes. That shift reinforces the company’s profile as a larger, more institutionally visible manufacturer at a time when it is taking on ZT Systems, expanding in AI and data center hardware, and investing heavily in North America and India, which many shareholders already view as central to the long term earnings and margin catalyst.

Yet, while LIBERTY adds an attractive new customer, investors also need to be aware that concentration in a few large AI and data center programs could...

Sanmina's narrative projects $19.2 billion revenue and $462.3 million earnings by 2029.

Uncover how Sanmina's forecasts yield a $223.75 fair value, a 7% upside to its current price.

Exploring Other Perspectives

Some of the lowest case analysts were already cautious, assuming revenue could reach about US$23.1 billion but with margins slipping toward 1.5 percent, and the news around LIBERTY and AI customer concentration may either soften or reinforce those worries, depending on how you think the next leg of Sanmina’s growth actually plays out.

Explore 4 other fair value estimates on Sanmina - why the stock might be worth as much as 7% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Sanmina research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Sanmina research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Sanmina's overall financial health at a glance.

Searching For A Fresh Perspective?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.